One of the key issues in organoid research is that it is impossible to add perfused human vasculature. Functional blood vessels are a vital connecting structure inside the body (‘in vivo’) and this aspect is lacking in conventional in vitro cell culture techniques. The vascularization of human tissue can therefore only be achieved in vivo by transplanting these tissues into mice that have been manipulated to lack an immune system. This to avoid rejection of the implant, denoted patient-derived xenograft (PDX).
The PDX process is extremely inefficient, costly, time-consuming, and can only be performed in limited numbers since it is missing throughput. Also, the human tissues are compromised by the ingrowth of murine tissue, including mouse vasculature, and thus not capturing the in vivo human situation. Facing these challenges and knowing that the entire PDX process is under high ethical pressure, we see a great unmet need for cell culture techniques that add human vasculature to in vitro cultured 3D tissues.
For this reason, we have expanded the OrganoPlate® family with the OrganoPlate® Graft. The first in vitro cell culture technique that allows vascularization of 3D tissues such as spheroids, organoids, and tumors.
OrganoPlate® Graft is a variation of the OrganoPlate 2-lane and 3-lane series and incorporates MIMETAS' unique technology to grow functional microvessels to create a microvascular bed. Tissue placed onto this bed is connected to the system of human blood vessels, achieving in vitro vascularization. This facilitates perfusion of the tissue and allows drug administration through the vasculature.
The OrganoPlate® Graft platform offers the possibility to vascularize a plethora of different tissue types on a standard SBS plate format and is compatible with a high-throughput workflow. It offers functionality that is not yet seen in the field of in vitro tissue culture modeling and has the potential to enhance current and future in vitro vascularization research.
James Sabry, Global Head
Roche Pharma Partnering
Head of Early Investigative Toxicology
From a top pharma
From a top pharma
From a top commercial organization
Laura Perin, PhD
Children’s Hospital Los Angeles
VectorY B.V., Netherlands
Therapeutic Developments and Innovative Strategies in Oncology: An Expert Discussion
Watch it here
The partnership comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies.
Read the full article here
Looking back at a Celebration of a Decade of Breakthroughs from our online anniversary event this past February, 9th, 2023.
Access the on-demand recordings here